NCT01619332View on ClinicalTrials.gov

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Type II Diabetes
Interventions
DRUG

Placebo

Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner

DRUG

Sitagliptin

Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner

DRUG

LEZ763

LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner

Trial Locations (6)

32809

Novartis Investigative Site, Orlando

33126

Novartis Investigative Site, Miami

37920

Novartis Investigative Site, Knoxville

45227

Novartis Investigative Site, Cincinnati

78209

Novartis Investigative Site, San Antonio

91910

Novartis Investigative Site, Chula Vista

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY